Northern New Jersey Community Clinical Oncology Program

描述(由申请人提供)：新泽西州北部CCOP(NNJCCOP) 提供癌症治疗和癌症控制的临床试验，以 新泽西州840万人口的近一半，以及邻近的 纽约和宾夕法尼亚州。43名医生有权参与试验， 包括儿童和成人血液学/肿瘤学家、外科医生、泌尿科医生、 放射肿瘤学家、妇科肿瘤学家和泌尿科医生。增加37个 医生积极参与CCOP的工作。广泛的外联 确保为癌症控制提供广泛的医生转介。它们由一个 训练有素的科研护士、药剂师和数据管理员。这个 CCOP创建了一个高效且经验丰富的基础设施，以确保 遵守最高标准的临床研究。医生们 建立在三个临床医院紧密结合的悠久传统基础上 两个组成部分的医院的地点。哈肯萨克大学医学中心(HUMC) 包括一个儿科项目，明日儿童？S研究所和一个 成人项目，新泽西北部癌症中心(NNJCC)。特里尼塔斯 医院，一个组成部分的医院驻扎在联合县，提供高 少数族裔人口。这两家医院是肿瘤科护理的主要来源 在他们的集水区，总共增加了2400多种新的癌症 每年都有病人。该计划的具体目标是：减少癌症 扩大临床试验的发病率、发病率和死亡率； 开发具有创造性和创新性的沟通、协作和 在医生、卫生保健提供者和公民中进行加速癌症的教育 预防、检测和治疗；确保更广泛地参与试验 在少数群体和女性参与者中；并确保高标准的 癌症试验中的卓越和高质量。强有力的领导，有效的 组织结构和可靠的记录支持以下目标 加速外联，广泛征聘，扩大应计范围，有效的后续行动， 准确的数据管理、符合质量保证标准和 积极参与新的临床试验的设计和实施。 在2002-2007年赠款期间，NNJCCOP预计将有1482名成年人应计 积分(420次治疗和1 062次癌症控制和随访)和318.2 儿科学分为298次治疗，癌症控制学分为20.2分。这 代表总共1800.2个贷项的5年期预计应计项目。

DESCRIPTION (provided by applicant): The Northern New Jersey CCOP (NNJCCOP) provides access to clinical trials for cancer treatment and cancer control to almost half of the 8.4 million population of New Jersey, as well as adjacent New York and Pennsylvania. Forty-three physicians have access to trials, including pediatric and adult hematology/oncologists, surgeons, urologists, radiation oncologists, gynecologic oncologists and urologists. 37 Additional physicians are actively involved in the work of the CCOP. Extensive outreach ensures broad physician referral for cancer control. They are supported by a well-trained cadre of research nurses, pharmacists and data managers. The CCOP has created an effective and experienced infrastructure to ensure compliance with the highest standards of clinical research. The physicians build on a long tradition of closely-knit integration at the three clinical sites at two component hospitals. Hackensack University Medical Center (HUMC) includes a pediatric program, Tomorrows Children?s Institute (TCI) and an adult program, the Northern New Jersey Cancer Center (NNJCC). Trinitas Hospital, a component hospital resides in Union County, serving a high minority population. The two hospitals are primary sources of oncology care in their catchment areas and together accrue more than 2400 new cancer patients each year. The specific aims of the program are to: reduce cancer incidence, morbidity and mortality through expansion of clinical trials; develop creative and innovative means of communication, collaboration and education among physicians, health providers and citizens to accelerate cancer prevention, detection and treatment; ensure broader participation in trials among minority and female participants; and assure high standards of excellence and quality in cancer trials. Strong leadership, an effective organizational structure and proven track record support the goals of accelerated outreach, broad recruitment, expanded accrual, effective followup, accurate data management, compliance with quality assurance standards and active participation in the design, and implementation of new clinical trials. For the grant period, 2002-2007, the NNJCCOP projects accrual of 1482 adult credits (420 treatment and 1062 cancer control and follow-up) and 318.2 pediatric credits with 298 treatments and 20.2 cancer control credits. This represents a combined 5-year projected accrual of 1800.2 credits.